Biocon's Pebrilzo wins EU approval for breast cancer use
In short
Biocon's Pebrilzo got European Union approval for HER2-positive breast cancer treatment. The update says the drug is Biocon's pertuzumab and that it is the first biosimilar to win European Commission marketing authorisation under the EMA's tailored clinical approach.
It may also help the company compete in the breast cancer treatment market there.
What the reporting says
Biocon's Pebrilzo won European Union approval for HER2-positive breast cancer treatment, according to the company update. The approval covers pertuzumab and was described as the first biosimilar to receive European Commission marketing authorisation under the EMA's tailored clinical approach. The clearance gives Biocon a regulatory milestone in the European market.
Why it matters
Biocon's Pebrilzo received European Union approval for use in HER2-positive breast cancer treatment. The approval is a regulatory step for Biocon in the European pharmaceuticals market and may support its biosimilar business.